Eric OBrien - 02 Feb 2022 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC

Role
Director, 10%+ Owner
Signature
/s/ David Kennedy, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
02 Feb 2022
Net transactions value
+$7,000,000
Form type
4
Filing time
04 Feb 2022, 18:32:38 UTC
Next filing
08 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GRNA Common Stock Award +8,201,814 8,201,814 02 Feb 2022 by Fall Line Endurance Fund, LP F1, F2
transaction GRNA Common Stock Purchase $7,000,000 +700,000 +8.5% $10.00* 8,901,814 02 Feb 2022 by Fall Line Endurance Fund, LP F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Issued pursuant to the terms of a business combination agreement involving the issuer and GreenLight Biosciences, Inc. in exchange for capital stock previously issued by such company.
F2 Mr. O'Brien, a director of the Issuer, is the co-founder and Managing Director of Fall Line Endurance Fund, LP and has the power to vote, or to direct the voting of, the shares held by Fall Line Endurance Fund, LP. By virtue of the foregoing, Mr. O'Brien may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the shares held by Fall Line Endurance Fund, LP. Mr. O'Brien disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.
F3 Amount consists of 700,000 shares of common stock issued pursuant to a subscription agreement entered into between the Issuer and Fall Line Endurance Fund, LP.